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Abstract
Background Acromegaly is a rare, debilitating condition
for which data on the associated treatment patterns and
economic burden are limited.
Objective Our objective was to examine patient charac-
teristics, treatment patterns, and healthcare resource uti-
lization (HRU)/costs for individuals with acromegaly
treated with surgical and/or medical therapy in the USA.
Methods Using a large US claims database, adults with
new episodes of acromegaly between 1 July 2007 and 31
December 2010 were identified (the first observed diag-
nosis being the index date). Patients had 6-month pre-index
and 12-month post-index continuous enrollment and sur-
gical and/or medical treatment during the 12-month post-
index period. Descriptive analysis was performed to
observe demographic/clinical characteristics, treatment
patterns, HRU, and monthly healthcare costs between two
mutually exclusive surgically and medically treated
cohorts.
Results This study included 228 acromegalic individuals
treated with surgical therapy and 169 treated with medical
therapy. During the 12-month follow-up, compared with
the medical cohort, the surgical cohort were more likely to
have hypertension (50.4 vs. 32.0 %), sleep apnea (31.6 vs.
15.8 %), cardiac dysrhythmia (16.7 vs. 7.0 %), hospital-
izations (98.3 vs. 13.6 %), and emergency room visits
(29.8 vs. 20.7 %), and had more outpatient visits (10.2 vs.
5.2) and physician office visits (21.2 vs. 15.0) (all differ-
ences, p\ 0.05). The surgical cohort had lower monthly
healthcare costs during the 6-month pre-index period
($US1963.5 vs. 2818.4) but higher costs in the 12-month
post-index period ($US5202.6 vs. 3076.5) than the medical
cohort.
Conclusions Our findings suggest the treatment pathway
observed in this patient population has a non-negligible
association with the clinical and economic burden.
Key Points
To address known data gaps, this study analyzed
patients in a large US administrative claims database
who had received surgical therapy and/or medical
therapy for newly recognized episodes of
acromegaly, in order to assess the prevalence of
comorbid conditions, treatment patterns, health
resource utilization, and costs.
Compared with patients given medical therapy, those
treated with surgical therapy had lower monthly
healthcare costs during the 6-month pre-index
period, and a higher prevalence of hypertension,
sleep apnea, cardiac rhythm problems, and abnormal
glucose, and higher costs in the 12-month post-index
period.
Future research is needed to assess the incremental
economic burden associated with acromegaly and
the cost-effectiveness of treatment options that cure
the disease or decelerate its progression.
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1 Introduction
Acromegaly is a debilitating disorder characterized by
overgrowth of tissues throughout the body. It is caused by
chronic growth hormone (GH) excess, typically due to a
benign pituitary adenoma [1] that develops gradually [2].
The condition is rare, with a prevalence of 58–130 cases
per million [3, 4]. Even so, the clinical and quality-of-life
burden posed by acromegaly is considerable. This is partly
because patients often present with chronic comorbid
conditions such as diabetes, hypertension, or valvular heart
disease [5] or may require lifelong treatment. Also, evi-
dence suggests that over half of patients with acromegaly
are not treated effectively with respect to achieving disease
control and minimizing adverse events such as nausea,
vomiting, and headache [5, 6]. Furthermore, overall stan-
dardized mortality rates for those with disease are
approximately twice those in the general population [7].
Such factors emphasize the importance of early diag-
nosis and optimal treatment, which can mitigate the
increased mortality risk [8]. In this context, recent treat-
ment guidelines recommend that first-line treatment for
acromegaly in most cases is tumor excision surgery where
the pituitary adenoma is resectable and the patient is a
suitable surgical candidate [5]. Crucially, such treatment is
potentially curative, and has an initial remission rate of
over 85 % for microadenomas and 40–50 % for
macroadenomas when performed by experienced surgeons
[9, 10]. However, repeat operations may be needed for
patients with residual intrasellar disease following initial
surgery [9, 10].
By comparison, the guidelines recommend medical
therapy as a first-line intervention only when surgery is not
recommended, for example, where it is contraindicated or
the tumor is unresectable. Medical therapy is also advo-
cated as second-line treatment where disease persists fol-
lowing surgery, cavernous sinus invasion is extensive,
there is no chiasmal compression, or the tumor recurs [5].
Also, many patients initially treated with medical therapy
will eventually need surgery. While medical therapy aims
primarily to control symptoms, it is commonly accompa-
nied by tumor shrinkage within 3 months of starting the
treatment [9, 10]. Drug therapy for acromegaly may also
have beneficial effects on comorbidities. Treatment
guidelines recommend radiotherapy as a possible treatment
when there is a residual tumor mass following surgery and
if medical therapy is unavailable or not tolerated [9, 10].
Radiotherapy is generally used as a third-line therapy, and,
when used alone or with surgery or medical therapy, is
likely to effect disease control [5, 6]. However, it is a more
risky option, which may lead to hypopituitarism, visual
defects, secondary tumors, and cerebrovascular events [5,
6]. Ultimately, surgical and medical therapies are the two
mainstay treatments for acromegaly, with a multimodal
approach often being needed.
While such treatment pathways for acromegaly are well-
established, there is much less clarity about real-world
treatment patterns for the disease and the related economic
burden. One of the few recently published studies on this
topic assessed data from 2003 to 2009 and found that total
healthcare costs associated with treating acromegalic
patients in the US were $US24,284 per patient-year, with
70 % from medical costs and 30 % from pharmacy costs
[11]. One recent study examined real-world clinical char-
acteristics and treatment patterns of individuals with
acromegaly in the US [5], and another study explored
treatment patterns, complications, and healthcare resource
utilization (HRU) associated with acromegaly [12]. Nota-
bly, both of these studies focused on prevalent cases.
Against this background, the objective of the current
study was to assess patients presenting with a new (and
possibly) first episode of acromegaly and treated initially
with either surgical excision or medical therapy, specifi-
cally to compare clinical characteristics, treatment patterns,
HRU, and costs between these treatment groups. Accord-
ingly, we applied a study design that specifically aimed to
capture evidence on such patients and to allow evaluation
of the initial treatment and add-on/switch therapies.
2 Methods
2.1 Data Source
Data for this retrospective study were obtained from the
Truven MarketScan Commercial Claims Databases
(Truven Health AnalyticsTM, Ann Arbor, MI, USA). These
databases contain data (1995–present) for over 150 million
patients residing in all US census regions, representing the
healthcare experience of employees and dependents [13].
The MarketScan Research databases provide information
on patient demographics and health plan enrollment, and
capture person-specific HRU and costs across hospital
inpatient and outpatient services, physician office visits,
home health, hospice, and prescription medications. The
commercial databases include large employers, health
plans, government organizations, and public organizations,
and cover approximately 100 payers and more than 500
million claims records. The databases link paid claims and
encounter data to detailed patient information across
healthcare settings and types of providers over time. Patient
and provider information contained in these databases are
de-identified, thus maintaining full compliance with the
privacy regulations of the Health Insurance Portability and
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Accountability Act of 1996. Data records examined for this
study spanned the time period from 1 January 2007 through
31 December 2011.
2.2 Patient Selection Criteria
Individuals aged 18 years or older, with two or more
medical claims at least 30 days apart between 1 July 2007
and 31 December 2010 (the date range), with a diagnosis of
acromegaly (primary or secondary International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
[ICD-9-CM] diagnosis code of 253.0) were selected. The
data records covered 1 January 2007 through 31 December
2011 (the data records range), so the 1 July 2007 through
31 December 2010 date range was chosen to ensure that all
included individuals would have at least a 6-month pre-
selection period and a 12-month post-selection period for
(1) an assessment of continuous health plan enrollment and
(2) an assessment of baseline comorbid conditions, HRU,
and costs. The first observed diagnosis was denoted as the
index date. In order to identify those with a new episode of
acromegaly, individuals with a medical claim with a
diagnosis of acromegaly in the 6-month pre-index period
were excluded. For example, if an individual with acro-
megaly had an index date of 15 July 2007 using claims in
the date range, but also had a claim with a diagnosis of
acromegaly on 14 March 2007 (in the data records range
but out of the date range), this individual was excluded
from the final sample size after applying this selection
criterion. Individuals were required to have either surgical
or medical therapy during the 12-month post-index period.
2.3 Study Populations and Identification
of Treatment Cohorts
Patients were assigned into cohorts based only on whether
they received surgery or medical therapy. Specifically,
each individual with acromegaly was categorized into two
mutually exclusive cohorts based on whether they received
(1) tumor resection surgery (see Sect. 6 for procedure
codes) with/without medical therapy (surgical therapy
cohort) or (2) medical therapy without surgery (medical
therapy cohort). Medical therapy included somatostatin
analog treatment (i.e., lanreotide depot, octreotide,
octreotide long-acting release [LAR], growth hormone
receptor antagonists [i.e., pegvisomant], and dopamine
agonists [bromocriptine and cabergoline]).
2.4 Study Measures
Study measures included demographic characteristics
comprising age, sex, plan type, and US geographic region
(northeast, midwest, south, and west) assessed as of the
index date. The prevalence of acromegaly-related comor-
bidities in the baseline and post-index periods was derived
using claims dated during 6 months prior to and 12 months
after the index date, respectively. The comorbidities of
interest included visual-field defects, hypopituitarism,
osteoarthritis, arthropathy/arthralgia/synovitis, kyphosis
and scoliosis, vertebral fracture, carpal tunnel syndrome,
myopathy/myalgia, hypertension, cardiomyopathy, cardiac
hypertrophy, heart failure, valvular heart disease, cardiac
dysrhythmia/arrhythmia, nasal polyps, sleep apnea, dia-
betes, galactorrhea, menstrual abnormality, impaired
libido/impotence, colon polyp, and hyperhidrosis.
Treatment patterns during the 12 months following the
index date were also assessed. Measures of interest inclu-
ded tumor resection surgery, stereotactic radiotherapy, and
medical therapy. Treatment sequence in terms of first-line
and second-line treatments in the 12-month post-index
period was assessed. First-line treatment patterns included
tumor resection surgery and medical therapy. For individ-
uals who received tumor resection surgery as the first-line
treatment, subsequent treatment patterns were examined,
including both medical therapy and no further treatment.
For patients who received medical therapy as the first-line
treatment, subsequent treatment patterns were examined,
including no second-line therapy (i.e., patients who either
continued to use the initial drug or completely discontinued
its use throughout the 12-month post-index period), add-on,
switching, and tumor resection surgery. Add-on was
defined as adding another drug to the initial drug, and
switching referred to discontinuing the initial drug and
starting another drug.
HRU measures included inpatient hospitalization,
emergency room (ER) visits, outpatient visits, physician
office visits, and the use of specialty care (i.e., endocri-
nologist, neurosurgeon, or oncologist visits). These mea-
sures were assessed for both the 6-month pre-index and
12-month post-index periods. Monthly total healthcare
costs were assessed during the 6-month pre-index and
12-month post-index periods. The cost categories included
inpatient, outpatient, and pharmacy costs. All-cause and
acromegaly-associated healthcare costs were estimated.
Since the index date was set as the date of the initial
diagnosis of the new episode of acromegaly, the acrome-
galy-associated healthcare costs could be captured only
during the post-index period. Acromegaly-associated
healthcare costs were defined as costs recorded on medical
claims with at least one ICD-9-CM diagnosis code sug-
gesting acromegaly (253.0), or costs reported on pharmacy
claims with acromegaly-associated medical therapy
including somatostatin analogs, growth hormone receptor
antagonists, and dopamine agonists. As individuals entered
and exited the study during different years, cost measures
were standardized to $US, year 2011 values, using
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inflationary factors [14]. A total cost perspective, which
included both healthcare payments plus any patient
copayments/deductibles, was used for this analysis. To
standardize cost comparisons, since the duration of pre-
index and post-index periods differed, we reported
healthcare costs on a monthly, rather than annual, basis.
2.5 Data Analyses
Descriptive analyses were conducted, and means and
standard deviations (SDs) were reported for continuous
variables in demographic characteristics and HRU. Per-
centages were reported for categorical variables in demo-
graphics, clinical characteristics, and HRU. Frequency
distributions with percentages were reported for treatment
sequences.
All-cause monthly total healthcare costs and cost by
settings were compared between study cohorts. The non-
parametric Wilcoxon test was used to detect differences for
cost variables. Proportions of acromegaly-associated
monthly healthcare costs, out of all-cause costs, were
presented overall and separately for inpatient costs, out-
patient costs, and pharmacy costs in the 12-month post-
index period.
An additional subgroup analysis was conducted on a
subset of individuals with at least 2 years of post-index
data. All-cause monthly total healthcare costs and cost by
settings for the 6-month pre-index period, and the first-year
and second-year post-index periods were presented for this
sub-sample. The percentages of acromegaly-associated
monthly total healthcare costs and cost by settings were




The study identified a total of 2492 commercially insured
individuals with acromegaly and at least two claims for the
disease between 1 July 2007 and 31 December 2010. After
applying all the inclusion/exclusion criteria, the final study
sample included 397 commercially insured individuals, of
whom 228 (57.4 %) received surgical therapy with or
without medical therapy and 169 (42.6 %) received med-
ical therapy without surgery during the study (Fig. 1).
3.2 Baseline Demographic Characteristics
Baseline patient demographic characteristics of acrome-
galic individuals by type of treatment are displayed in
Table 1. The mean (SD) age among individuals in the
medical therapy cohort (47.9 % female) and surgical ther-
apy cohort (49.6 % female) was 47.2 (10.5) and 46.4 (10.2)
years, respectively. Preferred provider organization (PPO)
health plans insured over half of the individuals in the
medical therapy cohort, with smaller proportions being
insured by health maintenance organization (HMO) plans
(18.9 %) and point of service (POS) plans (10.7 %). Over
four-tenths of the patients resided in the south region. In the
surgical therapy cohort, close to two-thirds of the individ-
uals had a PPO plan type, followed by 17.1 % with an HMO
plan and 8.8 % with a POS plan; over one-third resided in
the south region. Baseline demographic characteristics were
fairly well balanced between the two study cohorts.
Fig. 1 Sample selection of commercially insured acromegalic indi-
viduals who received surgical and/or medical therapy. * represents the
medical therapy cohort included individuals with acromegaly who
received medical therapy without surgery during the 12-month post-
index period;  represents the surgical therapy cohort included
individuals with acromegaly who received surgical therapy with/
without medical therapies during the 12-month post-index period
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3.3 Six-Month Pre-Index and 12-Month Post-Index
Clinical Characteristics
Acromegalic individuals, whether in the surgical or the
medical therapy cohort, had similar baseline clinical
characteristics except for sleep apnea (14.2 vs. 7.1 %,
respectively, p = 0.009) (Table 2). During the 12-month
post-index period, compared with the medical therapy
cohort, individuals in the surgical therapy cohort had a
higher prevalence of hypertension (50.4 vs. 32.0 %), sleep
apnea (31.6 vs. 15.8 %), cardiac dysrhythmia/arrhythmia
(16.7 vs. 7.0 %), and abnormal glucose (11.0 vs. 5.3 %)
(all differences, p\ 0.05).
3.4 Treatment Patterns and Healthcare Resource
Utilization
In the surgical therapy cohort, 31.6 % (72 of 228) of the
individuals also received medical therapy during the
12-month post-index period (Table 3). Regarding the pre-
scription medication used for treating acromegaly in the
medical therapy cohort, 37.9 % of individuals were pre-
scribed octreotide LAR, 37.3 % cabergoline, 16 % pegviso-
mant, 11.8 % bromocriptine, and 10.7 % lanreotide depot.
During the 6-month pre-index period, the overall pattern
of HRU was similar between the two study cohorts, except
that, compared with the medical therapy cohort, the sur-
gical therapy cohort had more hospital outpatient visits (2.9
vs. 2.2) and physician office visits (8.8 vs. 6.3), and a
higher proportion of patients in this cohort had neurosur-
geon visits (15.8 vs. 7.7 %) (all differences, p\ 0.05). In
the 12-month post-index period, these two cohorts showed
significant differences in the pattern of resource use.
Compared with the medical therapy cohort, the surgical
therapy cohort had a higher proportion of inpatient hospi-
talizations (98.3 vs. 13.6 %), ER visits (29.8 vs. 20.7 %),
and specialist office visits (68.0 vs. 54.4 %), and more
hospital outpatient visits (10.2 vs. 5.2) and physician office
visits (21.2 vs. 15.0) (all differences, p\ 0.05).
3.5 Treatment Sequence
Tumor resection surgery was used as the first-line treat-
ment in 50.9 % of individuals with new episodes of
acromegaly, of whom 77.2 % received no further treat-
ment and 22.8 % received medical therapy as the second-
line treatment. Medical therapy was used as the first-line
treatment in 49.1 % of individuals with acromegaly, of
whom 72.3 % did not receive second-line therapy, 12.3 %
received second-line surgical therapy, 7.7 % had add-ons
to the initial drug, and 7.7 % switched to another medi-
cation (Fig. 2).










18–44 years 37.9 37.7
45–54 years 34.3 37.7
55–64 years 27.8 24.6
Mean age (SD) 47.2 (10.5) 46.4 (10.2) 0.450
Sex




Point of service 10.7 8.8
Preferred provider organization 56.2 66.2









Data are presented as percentages, unless otherwise indicated
SD standard deviation
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3.6 All-Cause Costs and Acromegaly-Associated
Costs
During the 6-month pre-index period, individuals in the
medical therapy cohort had higher monthly total healthcare
costs ($US2818.4 vs. 1963.5) and pharmacy costs
($US1041.5 vs. 175.3) but lower monthly outpatient costs
($US929.6 vs. 1038.1) than the surgical therapy cohort (all
p\ 0.01). In the 12-month post-index period, individuals
in the medical therapy cohort had lower monthly total
healthcare costs ($US3076.5 vs. 5202.6), inpatient costs
($US347.7 vs. 2807.7), and outpatient costs ($US1366.6
vs. 1938.1) but higher pharmacy costs ($US1362.3 vs.
456.9) than did the surgical therapy cohort (all differences,
p\ 0.01) (Table 4).
Among the medical therapy cohort, the following
proportions of various costs were associated with acro-
megaly: 56.0 % of monthly total healthcare costs,
25.8 % of inpatient costs, 33.3 % of outpatient costs, and
86.6 % of pharmacy costs. By comparison, in the sur-
gical therapy cohort, the proportions were 52.5 % of the
monthly total healthcare costs, 72.5 % of inpatient costs,
21.8 % of outpatient costs, and 59.3 % of pharmacy
costs.
3.7 Subgroup Analysis in Patients with at Least 2
Years of Follow-Up
There were 240 acromegalic individuals with at least
2 years of post-index data. In the medical therapy cohort
Table 2 Six-month pre-index and 12-month post-index clinical characteristics in commercially insured acromegalic individuals, by study cohort











Visual-field defects 0.6 1.8 0.082 3.1 4.8 0.103
Hypopituitarism 5.3 13.6 0.665 4.4 16.2 0.471
Musculoskeletal
Osteoarthritis 7.7 14.2 0.593 9.2 13.6 0.863
Arthropathy/arthralgia/synovitis 12.4 20.1 0.860 11.8 19.3 0.839
Kyphosis and scoliosis 0.0 1.2 0.134 1.3 0.9 0.763
Vertebral fracture 0.0 1.2 0.134 1.3 0.4 0.397
Carpal tunnel syndrome 0.6 2.4 0.127 2.6 4.4 0.281
Myopathy/myalgia 3.6 4.1 0.597 2.6 5.7 0.482
Cardiovascular
Hypertension 23.7 34.3 0.068 32.0 50.4 0.001
Cardiomyopathy 0.6 1.8 0.127 2.6 3.5 0.298
Cardiac hypertrophy 1.2 3.0 0.645 1.8 4.4 0.461
Heart failure 0.0 1.8 0.053 2.2 2.2 0.770
Valvular heart disease 3.0 5.3 0.350 4.8 7.9 0.315
Cardiac dysrhythmia/arrhythmia 3.0 9.5 0.074 7.0 16.7 0.039
Respiratory
Nasal polyps 0.6 1.2 0.831 0.4 2.6 0.310
Sleep apnea (obstructive and central) 7.1 14.2 0.009 15.8 31.6 \0.001
Endocrine/metabolic
Diabetesa 14.8 23.1 0.536 17.1 27.2 0.352
Abnormal glucose 1.8 5.3 0.072 5.3 11.0 0.047
Galactorrhea 1.8 1.2 0.428 0.9 0.4 0.397
Menstrual abnormality 7.1 8.9 0.448 5.3 7.9 0.726
Impaired libido/impotence 1.2 3.6 0.310 2.6 4.0 0.837
Other
Colon polyp 2.4 5.9 0.668 1.8 10.5 0.105
Hyperhidrosis 0.6 0.0 0.196 2.2 2.2 0.053
a Excluding impaired glucose tolerance
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(N = 117), monthly total healthcare costs, outpatient costs,
and pharmacy costs were slightly greater during the sec-
ond-year post-index period followed by costs during the
first-year post-index period (Table 5). In the surgical
therapy cohort (N = 123), monthly total healthcare costs,
inpatient costs, and outpatient costs were highest during the
first-year post-index period, and monthly pharmacy costs
were highest during the second-year post-index period.
During the first-year post-index period, the surgical therapy
cohort had much higher monthly total healthcare costs
($US5204.4 vs. 2807.6), inpatient costs ($US2706.0 vs.
268.0), outpatient costs ($US2031.4 vs. 1071.6), and lower
pharmacy costs ($US467.1 vs. 1468.1) than did the medical
therapy cohort (all differences, p\ 0.01). However, this
trend was reversed to some extent in the second-year post-
index period, in that the surgical therapy cohort had lower
monthly total healthcare costs ($US2158.5 vs. 2919.1) and
outpatient costs ($US1082.2 vs. 1135.0) than the medical
therapy cohort (both differences, p\ 0.05).
4 Discussion
This study analyzed a large administrative claims database
to assess the cross-sectional prevalence of comorbid con-
ditions, treatment patterns/sequence, HRU, and costs among
commercially insured individuals with newly recognized
episodes of acromegaly who received surgical therapy and/
or medical therapy in the USA. Consistent with the study by
Burton et al. [5], we found that the prevalence of several
major comorbidities was higher among the acromegalic
individuals who received surgical and/or medical therapy
Table 3 Treatment patterns during the 12-month post-index period and healthcare resource utilization during the 6-month pre-index and
12-month post-index periods in commercially insured acromegalic individuals, by study cohort











Tumor resection surgery NA NA NA 0.0 100.0 NA
Stereotactic radiosurgery radiotherapy NA NA NA 3.0 4.8 0.350
Medical therapy NA NA NA 100.0 31.6 \0.001
Somatostatin analogue treatment
Lanreotide depot NA NA NA 10.7 11.0 0.921
Octreotide NA NA NA 6.5 9.2 0.328
Octreotide LAR NA NA NA 37.9 11.0 \0.001
Growth hormone receptor antagonists
Pegvisomant NA NA NA 16.0 5.3 \0.001
Dopamine agonists
Bromocriptine NA NA NA 11.8 2.6 \0.001
Cabergoline NA NA NA 37.3 5.7 \0.001
Healthcare resource utilization
Hospitalization admissions 11.2 10.1 0.711 13.6 98.3 \0.001
Number of inpatient admissions 0.2 (0.5) 0.1 (0.5) 0.716 0.2 (0.7) 1.2 (0.6) \0.001
Length of stay 1.1 (5.7) 0.6 (2.4) 0.694 1.1 (6.0) 4.0 (3.5) \0.001
Hospital outpatient visits 59.8 68.4 0.074 81.1 94.7 \0.001
Number of visits 2.2 (4.1) 2.9 (4.8) 0.014 5.2 (6.9) 10.2 (10.4) \0.001
Emergency room visits 12.4 18.9 0.085 20.7 29.8 0.041
Number of visits 0.1 (0.4) 0.5 (2.8) 0.063 0.4 (1.3) 0.8 (3.1) 0.015
Physician office visits 87.6 93.0 0.067 99.4 98.7 0.475
Number of visits 6.3 (6.7) 8.8 (8.7) \0.001 15.0 (13.3) 21.2 (14.3) \0.001
Specialist office visits 33.1 34.2 0.823 54.4 68.0 0.006
Endocrinologist 26.6 23.3 0.440 51.5 61.4 0.048
Neurosurgeon 7.7 15.8 0.015 7.1 20.2 \0.001
Oncologist 1.2 1.8 0.645 4.1 6.6 0.294
Data are presented as % or mean (standard deviation) unless otherwise indicated
LAR long-acting release, NA not available
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during the post-index period. Of note, Broder et al. [12]
concluded that complications associated with acromegaly,
especially cardiovascular and musculoskeletal abnormali-
ties, hypopituitarism, and sleep apnea, were commonly seen
in individuals with acromegaly and increased utilization and
costs in acromegaly patients; similarly, our study indicated
that the clinical burden is substantial in this population. In
addition, we observed that acromegalic individuals treated
Fig. 2 Treatment sequence of commercially insured acromegalic
individuals who received surgical and/or medical therapy during the
12-month post-index period. * represents the surgical therapy cohort
(N = 228) included individuals with acromegaly who received
surgical therapy as the first-line treatment (N = 202), as the
second-line treatment (N = 24), or as the third-line treatment
(N = 2); these two patients received surgery as the third-line
treatment after they switched from one drug (first-line) to another
drug (second-line); data not shown on this figure;  indicates that
another drug was added to the initial drug;  indicates that octreotide
and octreotide long-acting release (LAR) were considered as one
drug, and switching between octreotide and octreotide LAR was not
considered as a switch of drug; $ indicates that the initial drug was
discontinuded and another drug started
Table 4 Monthly total healthcare cost and cost by settings during the 6-month pre-index and 12-month post-index periods of commercially
insured acromegalic individuals, by study cohort














Total healthcare cost per month 2818.4 (5714.8) 1963.5 (4253.7) 0.009 3076.5 (3723.7) 5202.6 (3423.0) \0.001
% of total healthcare cost attributable to
acromegaly-associated total healthcare cost
NA NA 56.0 52.5
Cost of inpatient stays per month 847.4 (4803.5) 750.1 (3321.6) 0.739 347.7 (1332.0) 2807.7 (2021.1) \0.001
% of inpatient cost attributable to
acromegaly-associated inpatient cost
NA NA 25.8 72.5
Cost of outpatient care per month 929.6 (2683.4) 1038.1 (1685.3) \0.001 1366.6 (2829.3) 1938.1 (2201.6) \0.001
% of outpatient cost attributable to
acromegaly-associated outpatient cost
NA NA 33.3 21.8
Pharmacy costs per month 1041.5 (1561.0) 175.3 (405.8) \0.001 1362.3 (1692.7) 456.9 (788.9) \0.001
% of pharmacy cost attributable to
acromegaly-associated pharmacy cost
NA NA 86.6 59.3
Data are presented as mean (standard deviation) unless otherwise indicated; costs are presented as $US
Statistical comparisons of cost were made using the Wilcoxon rank-sum test
NA not available
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with surgical therapy had a higher prevalence of hyperten-
sion, sleep apnea, cardiac dysrhythmia/arrhythmia, and
abnormal glucose than those treated with medical therapy
during the post-index period. The impact of these compli-
cations was reflected in the higher healthcare costs.
During the 6-month pre-index period, healthcare resource
use was comparable between the two study cohorts; how-
ever, individuals in the surgical therapy cohort utilizedmuch
greater resources in all healthcare settings than did those in
the medical therapy cohort during the 12-month post-index
period, suggesting a considerable economic burden associ-
ated with resection surgery and post-operative follow-up.
The trend from cost analyses further validated this finding
and showed that the surgical therapy cohort actually incur-
red lower costs during the pre-index period but had much
higher costs in the 12-month post-index period compared
with the medical therapy cohort. In our study, the surgery
cohort comprised 228 patients, including 156 and 72 indi-
viduals with and without medical therapy, respectively. It is
therefore possible that the costs could be higher in the sur-
gical cohort at least partly due to this inclusion of patients
with combination therapy, and that the costs associated with
surgical treatment alone might be considerably lower. This
notion is potentially supported by the fact that the overall
proportion of patients treated with surgery for new episodes
of acromegaly is somewhat lower than would be expected
for a truly incident population. This fact suggests that our
sample would have included some patients who were in fact
presenting with disease recurrence, so accounting for the
low proportion that went on to have surgery as first-line
treatment (compared with a typical rate for a truly incident
group) and the considerable number of such individuals who
also needed second-line medical treatment.
Interestingly, our analysis of individuals with at least
2 years of post-index data is in line with the idea that, in the
longer term, surgery may ultimately be associated with
lower costs. Specifically, subgroup analysis showed that
monthly total healthcare costs, inpatient costs, and outpa-
tient costs were higher during the first-year post-index
period and lower during the second-year post-index period
in the surgical therapy cohort. This might have reflected
favorable longer-term outcomes among individuals treated
with surgery early after the initial acromegaly diagnosis. Of
relevance, a study by Wilson et al. [15] on the economic
burden among 53 Canadian patients with acromegaly who
received a surgical procedure only (n = 27) or along with
medical therapy (n = 26) observed that the mean annual
surgical costs when averaged over 4 years was $US2400
less than the cost of medications. We also observed a pos-
itive relationship between drug costs and time, suggesting
that, despite receiving costly surgical procedures, some
individuals had persistent disease requiring subsequent
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patients in our surgical cohort could have had recurrent
episodes of acromegaly, and were consequently less likely
than incident patients to be cured with surgery alone. In the
medical therapy cohort in our study, total healthcare costs
were slightly higher during the second-year post-index
period, primarily owing to the rising costs in the outpatient
and pharmacy settings. Inpatient costs were the lowest
during the second-year post-index period, perhaps sug-
gesting that pharmacologic treatments were effective in
preventing patients from experiencing acute and severe
complications that necessitated hospitalization.
Future research should (1) explore patient characteristics
associated with individuals who could not achieve surgi-
cally induced remission, (2) investigate other cost-effective
treatment options for these individuals, and (3) use a longer
follow-up period to accurately capture treatment patterns
over time. It is important to understand the projection of
lifetime costs of surgical versus medical therapy for acro-
megaly in future studies to establish whether the overall
costs of medical treatment will rapidly overtake the upfront
high surgical cost, and whether or how this differs for
patients with newly diagnosed and recurrent disease.
4.1 Limitations
This study was subject to the following limitations common
to most retrospective database analyses. The economic
analysis was conducted from a total cost perspective, which
included healthcare payments and any patient copayments/
deductibles. Other costs such as indirect costs related to lost
wages or lowered productivity were not considered.
Healthcare claims used in this analysis were primarily used
for administrative purposes in obtaining reimbursement for
services provided to health plan members; hence, potential
diagnostic and procedural coding inaccuracies might have
occurred, causing the misclassification of certain diagnoses,
events, or procedures of interest. It is possible that comor-
bidities might be underestimated, since coding for potential
comorbidities may be poorly done, and, due to the nature of
claims data, no clinical records were available in the data-
base to evaluate acromegaly-associated comorbidities.
Other limitations included the potential for bias in treatment
cohort comparisons due to unmeasured confounders (e.g.,
disease severity, as the size and invasiveness of tumors were
not available in the database). In addition, we used only a
6-month pre-index period for excluding patients with a
diagnosis of acromegaly to identify newly recognized epi-
sodes of the condition and only required that individuals
with acromegaly have at least 6 months of continuous health
plan enrollment prior to the index date, to help ensure there
were sufficient patients for analysis in our study sample.
Acromegaly is challenging to diagnose and is often recog-
nized late. Also, due to the nature of the claims database, it
was not possible to know the disease history of the patient
outside the current study period. Therefore, it is important to
note that our study sample should not be regarded as a truly
incident population, owing to the short pre-index period.
More likely, it represents a mixture of patients, some of
whom would be newly diagnosed, with others presenting
with episodes of recurrent disease. We observed treatment
patterns only during the 12-month post-index period, which
may not have been a long enough period to capture the
comprehensive and longitudinal picture necessary to fully
understand patients’ treatment profiles. An important treat-
ment goal for patients with acromegaly is to achieve bio-
chemical control in terms of GH and insulin-like growth
factor (IGF)-1 level; however, GH and IGF-1 data were not
available in the current dataset. Another factor to consider
here is the that the surgery cohort included patients with and
without medical therapy, which—as mentioned above—we
cannot be sure how our results might compare with an
analysis that distinguished between cases that had surgery
alone, surgery with medical therapy, and medical therapy
alone in terms of economic burden, complications, and
hospital admissions—an important potential focus for future
research. Finally, given the dynamic pattern of care for
patients with acromegaly in the clinical community, results
derived from this study using data from 2007 to 2011 may
not accurately reflect the current treatment patterns or eco-
nomic burden of acromegaly.
5 Conclusions
Acromegaly poses a significant economic burden on indi-
vidual patients and society as a whole. There is a paucity of
published data with respect to the economic burden asso-
ciated with the condition stratified by type of treatment that
the patient initially receives. By comparing patient char-
acteristics, treatment patterns/sequence, and economic
outcomes associated with the type of acromegaly treat-
ment, our findings may provide insights to the healthcare
community and contribute to the literature. Future research
is needed to assess the incremental economic burden
associated with acromegaly and to conduct cost-effective
analysis on treatment options to cure or decelerate the
progression of the disease course.
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Appendix
Tumor resection surgery for acromegaly and associated
current procedural terminology (CPT) codes and Interna-
tional Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) procedure codes
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